Background {#Sec1}
==========

*Pneumocystis carinii* pneumonia occasionally appears in immunodeficient patients, particularly with the administration of chemotherapy. While several reports have shown that infliximab treatment \[[@CR1]--[@CR5]\], which is generally used for the treatment of rheumatoid arthritis and Crohn's disease, can lead to *Pneumocystis carinii* pneumonia \[[@CR6]--[@CR12]\], to the best of our knowledge, no case has demonstrated the development of pneumonia due to an increased dosage of infliximab treatment. The present case suggests that an increased dosage of infliximab is a potential cause of *Pneumocystis carinii* pneumonia.

Case {#Sec2}
====

A 51-year-old male was suffering Crohn's disease (CD) since 1990. The patient's weight was 67 kg. He had the inflammatory type of Crohn's disease, and the area of his lesion was the colon and small intestine. He had no complications, including intra- or extraenteral lesions, or any other systemic disorders. He had been taking 5 mg/kg of infliximab (total 400 mg) since 2004 and 0.15 g/day of 6-mercaptopurine since 2005. However, he complained of abdominal pain, his Harvey--Bradshaw index scores increased from 5 to 13, and he subsequently began taking 10 mg/kg of infliximab (total 650 mg) from September 2013. In January 2014, he complained of a fever and cough. Laboratory tests on this admission showed high levels of C-reactive protein and anti-mycoplasma antibody while other examination items, including the white blood cell count and T-SPOT, were unremarkable. A computed tomography (CT) scan revealed ground-glass opacities in the lower lobes of the bilateral lung with a crazy-paving pattern (Fig. [1](#Fig1){ref-type="fig"}a). Bronchoscopy detected swelling of the tracheal mucosa with obvious dilations of the vessels (Fig. [2](#Fig2){ref-type="fig"}). A bronchoalveolar lavage fluid sample obtained during bronchoscopy included 255 cells/field with 80 % macrophages, 12 % lymphocytes and 8 % neutrophils. A polymerase chain reaction using the bronchoalveolar lavage fluid sample detected specific sequences for *Pneumocystis jirovecii*. Taken together, he was diagnosed as having pneumonia due to the combined infection of *Mycoplasma* and *Pneumocystis carinii* (jirovecii). The patient stopped infliximab administration and took 2 g/day of ceftriaxone, 500 mg/day of azithromycin and 400 mg/80 mg/day of sulfamethoxazole/trimethoprim; thereafter his symptoms including a fever and cough improved. CT after the antibiotic therapy showed a significant improvement of the ground-glass opacities in the lower lobes of the bilateral lung (Fig. [1](#Fig1){ref-type="fig"}b).Fig. 1Computed tomography findings of the chest. Ground-glass opacities were seen in the lower lobes of the bilateral lung with a crazy-paving pattern on admission (**a**). Ground-glass opacities were improved after antibiotic therapy (**b**)Fig. 2Bronchoscopy finding. Swelling and obvious dilations of the vessels were seen in the tracheal mucosa on admission

Discussion {#Sec3}
==========

The present report demonstrated a case of *Pneumocystis carinii* pneumonia due to the increased dosage of infliximab. While several cases have demonstrated pneumonia due to *Pneumocystis carinii* after infliximab treatment, to the best of our knowledge, this is the first case in which an increased dosage of infliximab triggered pneumonia. A summary of previously reported cases and our case of *Pneumocystis carinii* pneumonia in CD patients is shown in Table [1](#Tab1){ref-type="table"}.Table 1Date on pneumocystis pneumonia during administrarion of infliximabNo.ReferenceYearSexAge at diagnosis (years)Crohn's disease durationIFX durationDose of IFXConcomitant drug(s)MedicationClinical course1Seddik et al. \[[@CR6]\]2004Male29ND1 month5 mg/kgPSL + AZAST2 weeks alive2Velayos et al. \[[@CR7]\]2004Male192 years2 years 3 months5 mg/kgAZAST + PSL2 weeks alive3Kaur et al. \[[@CR8]\]2004Male593 weeks9 weeksNDPSLST + PM1 month died4Stratakos et al. \[[@CR9]\]2005Female779 months8 months5 mg/kgmPSL + AZAST6 month alive5Itaba et al. \[[@CR10]\]2007Female5721 years5 weeks5 mg/kgPSL + AZAST + mPSL4 month alive6金井 et al. \[[@CR11]\]2009Male6944 years4 weeks5 mg/kg5-ASA + PSLST + mPSL6 month alive7Tshudy et al. \[[@CR12]\]2010Male86 years15 months5 mg/kgNoneST4 weeks alive8Present case2014Male5124 years10 years10 mg/kg6-MP (0.15 g/day)ST1 year 5 month alive*ST* sulfamethoxazole/trimethoprim, *PSL* prednisolone, *mPSL* methylprednisolone, *PM* pentamidine, *AZA* azathioprine, *5*-*ASA* mesalazine, *6*-*MP* 6mercaptopurine, *ND* not described

Of the seven cases, five were male and two were female. The age ranged from 8 to 77 years. While *Pneumocystis carinii* pneumonia appeared at 4 weeks to 29 months after starting infliximab treatment in previous reports, the present case exhibited pneumonia at 120 months after starting infliximab treatment, at 102 months after starting the 6-mercaptopurine treatment, 24 weeks after starting an increased dosage of infliximab from 5 to 10 mg/kg. This suggests that an increased dosage of infliximab is a potential cause of immunodeficiency, leading to *Pneumocystis carinii* pneumonia. Notably, all cases developing *Pneumocystis carinii* pneumonia took immunomodulators and/or steroids, suggesting that the combined use of these drugs is a risk for pneumonia. Because sulfamethoxazole/trimethoprim was effective for all cases, antibiotics should be immediately administered after the diagnosis of *Pneumocystis carinii* pneumonia.

Conclusions {#Sec4}
===========

The findings of the present case suggest that the administration of an increased dosage of infliximab, as well as a general dose of infliximab, can cause *Pneumocystis carinii* pneumonia in CD patients, particularly in patients taking immunomodulators and/or steroids, illustrating the need for follow up, including pulmonary symptoms and CT examinations, when increasing the dosage of infliximab in CD patients.

Consent {#Sec5}
=======
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